Temporal trends and predictors of perioperative chemotherapy use in elderly patients with resected nonsmall cell lung cancer

Cancer

Volumn 112, Issue 2, 2008, Pages 382-390

  Wang, Jue ^a   Yong, Fang Kuo ^b,c   Freeman, Jean ^b,c   Markowitz, Avi B ^b   Goodwin, James S ^b,c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

And End Results Medicare database; Chemotherapy; Epidemiology; Medicare beneficiaries; Nonsmall cell lung cancer; Surveillance

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; TAXANE DERIVATIVE;

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PERIOPERATIVE PERIOD; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MEDICARE; NEOPLASM STAGING; SEER PROGRAM; UNITED STATES;

EID: 38049045518     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23181     Document Type: Article

References (49)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
2. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2:533-543.
3. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004;350:379-392.
4. Immerman SC, Vanecko RM, Fry WA, Head LR, Shields TW. Site of recurrence in patients with stages I and II carcinoma of the lung resected for cure. Ann Thorac Surg. 1981;32:23-27.
5. Rosell R, Felip E, Maestre J, et al. The role of chemotherapy in early non-small-cell lung cancer management. Lung Cancer. 2001;34(suppl 3):S63-S74.
6. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997;111:1710-1717.
7. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 1995;311:899-909.
8. Le Chevalier T, for the IALT Investigators. Results of the Randomized International Adjuvant Lung Cancer Trial (IALT) cisplatin-based chemotherapy (CT) versus no CT in 1867 patients with resected non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 2003:22. Abstract 6.
9. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J;International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350:351-360.
10. Winton TL, Livingston R, Johnson D, et al. Vinorelbine and cisplatin vs observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352:2589-2597.
11. Strauss GM, Herndon JE, Maddaus MA, et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of Cancer and Leukemia Group B (CALGB) Protocol 9633 [abstract]. Proc Am Soc Clin Oncol. 2006;24:365.
12. Douillard J, Rosell R, Delena M, et al. ANITA: phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts); final results after 70-month median follow-up [abstract]. Proc Am Soc Clin Oncol. 2005;24:619.
13. Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small cell lung cancer. J Natl Cancer Inst. 2003;95:1453-1461.
14. Waller D, Peake MD, Stephens RJ, et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg. 2004;26:173-182.
15. Tada H, Tsuchiya R, Ichinose Y, et al. A randomized trial comparing adjuvant chemotherapy versus surgery alone for completely resected pN2 non-small cell lung cancer (JCOG9304). Lung Cancer. 2004;43:167-173.
16. Keller SM, Adak S, Wagner H, et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med. 2000;343: 1217-1222.
17. Goodwin JS, Hunt WC, Humble CG, Key CR, Samet JM. Cancer treatment protocols. Who gets chosen? Arch Intern Med. 1988;148:2258-2260.
18. Baldwin LM, Adamache W, Klabunde CN, et al. Linking physician characteristics and Medicare claims data: issues in data availability, quality, and measurement. Med Care. 2002;40(8 suppl):IV-82-IV-95.
19. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
20. Mackillop WJ, O'Sullivan B, Ward GK. Non-small cell lung cancer: how oncologists want to be treated. Int J Radiat Oncol Biol Phys. 1987;13:929-934.
21. Palmer MJ, O'Sullivan B, Steele R, Mackillop WJ. Controversies in the management of non-small cell lung cancer: the results of an expert surrogate study. Radiother Oncol. 1990;19:17-28.
22. Greco FA, Hainsworth JD. Paclitaxel-based therapy in non-small-cell lung cancer: improved third generation chemotherapy. Ann Oncol. 1999;10(suppl 5):S63-S67.
23. Greco FA, Burris HA 3rd, Gray JR, et al. Paclitaxel and carboplatin adjuvant therapy alone or with radiotherapy for resected nonsmall cell lung carcinoma: a feasibility study of the Minnie Pearl Cancer Research Network. Cancer. 2001;92:2142-2147.
24. Fagerlin A, Zikmund-Fisher BJ, Ubel PA. Cure me even if it kills me: preferences for invasive cancer treatment. Med Decis Making. 2005;25:614-619.
25. Langer CJ, Moughan J, Movsas B, et al. Patterns of care survey (PCS) in lung cancer: how well does current U.S. practice with chemotherapy in the non-metastatic setting follow the literature? Lung Cancer. 2005;48:93-102.
26. Chien CR, Lai MS. Trends in the pattern of care for lung cancer and their correlation with new clinical evidence: experiences in a university-affiliated medical center. Am J Med Qual. 2006;21:408-414.
27. Mahmud SM, Reilly M, Comber H. Patterns of initial management of lung cancer in the Republic of Ireland: a population-based observational study. Lung Cancer. 2003;41:57-64.
28. Logan DM, Lochrin CA, Darling G, Eady A, Newman TE, Evans WK. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group. Cancer Prev Control. 1997;1:366-378.
29. Choong NW, Vokes EE. Adjuvant and neoadjuvant therapy for early-stage non-small-cell lung cancer. Clin Lung Cancer. 2005;7(suppl 3):S98-S104.
30. Brown JS, Eraut D, Trask C, Davision AG. Age and treatment of lung cancer. Thorax. 1996;51:564-568.
31. de Rijke JM, Schouten LJ, ten Velde GP, et al. Influence of age, comorbidity and performance status on the choice of treatment for patients with non-small cell lung cancer; results of a population-based study. Lung Cancer. 2004;46: 233-245.
32. Earle CC, Venditti LN, Neumann PJ, et al. Who gets chemotherapy for metastatic lung cancer? Chest. 2000;117:1239-1246.
33. Goodwin JS, Hunt WC, Samet JM. Determinants of cancer therapy in elderly patients. Cancer. 1993;72:594-601.
34. Goodwin JS, Hunt WC, Samet JM. A population-based study of functional status and social support networks of elderly patients newly diagnosed with cancer. Arch Intern Med. 1991;151:366-370.
35. Goodwin JS, Hunt WC, Key CR, Samet JM. The effect of marital status on stage, treatment, and survival of cancer patients. JAMA. 1987;258:3125-3130.
36. Stiggelbout AM, Jansen SJ, Otten W, Baas-Thijssen MC, van Slooten H, van de Velde CJ. How important is the opinion of significant others to cancer patients' adjuvant chemotherapy decision-making? Support Care Cancer. 2007;15: 319-325.
37. Earle CC, Neumann PJ, Gelber RD, Weinstein MC, Weeks JC. Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol. 2002;20:1786-1792.
38. Luo R, Giordano SH, Freeman JL, Zhang D, Goodwin JS. Referral to medical oncology: a crucial step in the treatment of older patients with stage III colon cancer. Oncologist. 2006;11:1025-1033.
39. Luo R, Giordano SH, Zhang DD, Freeman J, Goodwin JS. The role of the surgeon in whether patients with lymph node-positive colon cancer see a medical oncologist. Cancer. 2007;109:975-982.
40. Gridelli C, Perrone F, Monfardini S. Lung cancer in the elderly. Eur J Cancer. 1997;33:2313-2314.
41. Rosell R, Gatzemeier U, Betticher DC, et al. Phase III randomised trial comparing paclitaxel/carboplatin versus paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol. 2002;13:1539-1549.
42. Lokich J, Anderson N. Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol. 1998;9:13-21.
43. Schiller JH, Harrington D, Belani CP, et al. Comparison of 4 chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med. 2002;346:92-98.
44. Simon GR, Bunn PA Jr. Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): recent developments. Cancer Invest. 2003;21:87-104.
45. Ramalingam S, Belani CP. Taxanes for advanced non-small cell lung cancer. Expert Opin Pharmacother. 2002;3:1693-1709.
46. Pepe C, Hasan B, Winton TL, et al.; National Cancer Institute of Canada, Intergroup Study JBR.10. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR. J Clin Oncol. 2007;25:1553-1561.
47. Giordano SH, Duan Z, Kuo YF, Hortobagyi GN, Goodwin JS. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol. 2006;24:2750-2756.
48. Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998;16:1582-1587.
49. Repetto L, Venturino A, Vercelli M, et al. Performance status and comorbidity in elderly cancer patients compared with young patients with neoplasia and elderly patients without neoplastic conditions. Cancer. 1998;82:760-765.